SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
Illustration of red paper plane leading white paper planes up into the sky
Cancer
5 Therapies Moving the Multiple Myeloma Space Forward
A “significant number of patients” could see a cure for multiple myeloma within the next two decades, one expert told BioSpace. Here are five therapies that could change the treatment paradigm.
March 9, 2026
 · 
8 min read
 · 
Tristan Manalac
FDA
FDA’s Prasad To Depart FDA Following Tumultuous Term as CBER Chief
Center for Biologics Evaluation and Research Director Vinay Prasad will exit the FDA for the second time after a controversial run that saw the oncologist butt heads with colleagues and ruffle feathers in biopharma after presiding over the rejection of several rare disease therapies.
March 6, 2026
 · 
3 min read
 · 
Heather McKenzie
Brain tumor medical poster. Cancer, metastasis or benign in the human head or in the nerves, pituitary gland, pineal gland, and membranes that cover the surface of the brain 3D vector illustration
Mergers & acquisitions
Servier Adds to Childhood Brain Tumor Portfolio With $2.5B Day One Buy
Servier will pick up Ojemda, which received FDA approval in 2024 to treat pediatric glioma. The drug clocked sales of $155 million for Day One Biopharmaceuticals in 2025.
March 6, 2026
 · 
1 min read
 · 
Annalee Armstrong
pills with dollar sign isolated on white background
Opinion
Direct-to-Consumer Drugs Are Not a Panacea for High Costs
TrumpRX and DTC sales may expand prescription drug access, but they will not solve the affordability crisis by themselves.
March 6, 2026
 · 
4 min read
 · 
Michael Grosberg
Recession, reduced revenue or lower profits, gold coins roll down following the falling arrow stock illustration
Weight loss
Roche, Zealand’s Amylin Weight Loss Drug Fails To Clear Lilly’s Bar
Zealand Pharma’s shares fell 32% in early morning trading Friday after its Roche-partnered asset petrelintide failed to meet investor expectations in a mid-stage clinical trial.
March 6, 2026
 · 
3 min read
 · 
Tristan Manalac
Pictured: Johnson & Johnson Business Center in Switzerland
Immuno-oncology
J&J Wins Third National Priority Approval for Multiple Myeloma Combo
The FDA granted Johnson & Johnson a Commissioner’s National Priority Voucher in December 2025 after the combination of Darzalex and Tecvayli improved progression-free survival by 83%. The new approval is for second-line treatment of the blood cancer.
March 6, 2026
 · 
2 min read
 · 
Tristan Manalac
Human brain with abstract visualization of neuron activity
Huntington’s disease
FDA Official Fires Back at UniQure, Doubles Down on Sham-Controlled Trial
UniQure does not have to drill placebo burr holes in the skulls of patients with Huntington’s disease, an unnamed FDA senior official said on Thursday. Instead, the company would anesthetize them and put “one to three nicks” in their scalp.
March 6, 2026
 · 
2 min read
 · 
Tristan Manalac
Model of human brain and pills to improve memory. 3D illustration.
Psychedelics
Psychedelics Are Placeholders for More Traditional Depression Therapies: Analysts
Psychedelics are a “game changer” in depression care, according to William Blair, but the complicated treatment regimens mean they will likely be supplanted by more-traditional options once they become available.
March 5, 2026
 · 
5 min read
 · 
Annalee Armstrong
Creative collage illustration of financial business. Two businessmen shaking hands for partners agreement. Conceptual illustration of success deal, corporate ethic, connection.
Cardiovascular disease
Alnylam Unites With Tenaya in Potential $1B+ Pact To Find New Genetic Heart Disease Targets
The alliance, which pairs Tenaya’s modality agnostic target identification and validation capabilities with Alnylam’s deep experience in RNA interference therapeutics, comes during a period of resurgence for the cardiovascular space.
March 5, 2026
 · 
2 min read
 · 
Heather McKenzie
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS